secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2026-09-16T20:05:25+00:00
Accession:  0001683168-26-007193
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma majority owner approves reverse split up to 1-for-20
-----------------------------------------------------------------------

- Dr. Steve N. Slilaty, CEO, holding ~97% voting power, approved reverse split via written consent on Sept 15, 2026.
- Board authorized to effect split at ratio up to 1-for-20, with exact whole-number ratio at board's discretion.
- Consent effective 20 days after definitive information statement mailed to stockholders.
- Split applies to common stock (SBFM); warrants (SBFMW) also listed on Nasdaq.
- No timeline for board decision; action allows flexibility to meet listing requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826007193/0001683168-26-007193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826007193/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer